Evaluating outcomes of sacituzumab govitecan (SG) in patients with urothelial cancer (UC), previously treated with enfortumab vedotin (EV)

被引：1
|
作者：
Vlachou, Evangelia [1 ]
Johnson, Burles Avner [2 ]
Hahn, Noah M. [3 ]
Rourke, Kelli [4 ]
Mcconkey, David James [4 ]
Hoffman-Censits, Jean H. [2 ]
机构：
[1] Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD USA
[2] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[3] Johns Hopkins Sch Med, Baltimore, MD USA
[4] Johns Hopkins Univ Hosp, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：567 / 567
页数：1
相关论文
共 50 条
  • [1] Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)
    Sternschuss, Michal
    Toumbacaris, Nicolas
    Das, Jeeban Paul
    Powles, Thomas
    Bajorin, Dean F.
    Kotecha, Ritesh R.
    Laccetti, Andrew Leonard
    Xiao, Han
    Feld, Emily
    McHugh, Deaglan Joseph
    Keegan, Niamh M.
    Funt, Samuel A.
    Shah, Neil J.
    Iyer, Gopa
    Aggen, David H.
    Teo, Min Yuen
    Ostrovnaya, Irina
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): Real-world experience.
    Vlachou, Evangelia
    Hahn, Noah M.
    Dabb, Alix
    Johnson, Burles Avner
    Lefande, M. Susan
    Hoffman-Censits, Jean H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naive UC (DAD-IO)
    McGregor, Bradley Alexander
    Kwak, Lucia
    Sonpavde, Guru P.
    Berg, Stephanie A.
    Choueiri, Toni K.
    Bellmunt, Joaquim
    Mantia, Charlene
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Comparison of single agent versus combination activity of enfortumab vedotin (EV) and sacituzumab govitecan (SG) in a panel of bladder cancer XPDX models
    Simonson, A.
    Flores, J.
    Mercer, G.
    Lopez, M.
    Garcia, R.
    Lund, J.
    Banos, N.
    Papadopoulos, K.
    Calvo, E.
    Pedregal, M.
    Hernandez, T.
    Rasco, D.
    Patnaik, A.
    Garcia-Foncillas, J.
    Wick, M.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S118 - S118
  • [5] Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Jiang, Cindy
    Alhalabi, Omar
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Davidsohn, Matthew
    Nizam, Amanda
    Taylor, Amy K.
    Nguyen, Charles B.
    Kilari, Deepak
    Pywell, Cameron
    Davis, Nancy B.
    Emamekhoo, Hamid
    Sonpavde, Guru P.
    Gupta, Shilpa
    Bellmunt, Joaquim
    Grivas, Petros
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer
    Hanna, Kirollos S.
    Larson, Samantha
    Nguyen, Jenny
    Boudreau, Jenna
    Bulin, Jennifer
    Rolf, Mallory
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (08) : 629 - 635
  • [7] Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer
    Zhou, Yuzhen
    D'Andrea, Vincent D.
    Shanmugam, Surish P.
    Stelter, Isabella
    Stormoen, Dag R.
    Chroneos, Rea
    Hanlon, Timothy
    Epstein, Ilana
    Bekele, Raie T.
    Anderson, William J.
    Carvalho, Filipe F. L.
    Bellmunt, Joaquim
    Mouw, Kent W.
    EUROPEAN UROLOGY, 2024, 86 (01)
  • [8] Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
    Powles, Thomas
    Rosenberg, Jonathan E.
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Wu, Chunzhang
    Campbell, Mary
    Matsangou, Maria
    Petrylak, Daniel P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1125 - 1135
  • [9] Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2022, 207 (01): : 228 - 228
  • [10] Enfortumab vedotin (EV): Efficacy comparison with trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) and its potential for combination benefit in bladder cancer XPDX models
    Flores, Johnnie
    Sessions, Heaven
    Simonson, Alyssa
    Banos, Natalia
    Rouzbahani, Tahmineh
    Diaz, Armando, III
    Lund, Jim
    Calvo, Emiliano
    Moreno, Victor
    Papadopoulos, Kyriakos
    Rasco, Drew
    Patnaik, Amita
    Ulmer, Scott
    Rodriguez, Luis
    Wick, Michael
    CANCER RESEARCH, 2024, 84 (06)
12345